The researchers said that a study to validate their concept showed that the platform has potential to detect cancer and infectious disease biomarkers in human blood.
The company is collating data on physician decision-making from early-access users, and believes that it can make a strong case for clinical utility of the test.
The Fondazione Luigi Maria Monti - Istituto Dermopatico dell' Immacolata research hospital in Rome will perform SelectMDx testing locally.
The companies will work together to develop a series of cancer screening tests that employ Preora's cytology platform and its sample-preparation technologies.
Excluding the sale of the company's colorectal cancer patents to Exact Sciences, its 2017 revenues rose 13 percent.
The updated recommendations discuss testing for DNA repair gene mutations, MSI-H, and dMMR, as well as germline testing and counseling.
The firm has partnered with the University of Surrey to validate and potentially commercialize a test that detects mRNA biomarkers from patient urine samples.
The company discussed its efforts to grow adoption of its products during a call to discuss second quarter financial results for fiscal year 2018.
UgenTec will develop artificially intelligent software to support interpretation of MDxHealth's ConfirMDx and SelectMDx molecular prostate cancer tests.
The coverage decision is based on the results of an evidence development study the companies launched last year.